The direct-to-consumer telehealth startup will go public through a merger with special purpose acquisition company Oaktree Acquisition Corp. The combined entity is expected to be valued at $1.6 billion.
Plume provides access to telehealth consultations for patients seeking gender-affirming hormone therapy. Recently, the startup began partnering with employers to offer its services as a benefit.
Thirty Madison, which owns direct-to-consumer pharmacy brands for hair loss, migraines and acid reflux, raised $47 million in a series B round. Polaris Partners led the round, and Johnson & Johnson participated as an investor.